1.Study on Preparation of Immobilized Thrombin Treated with Silk Fibroin
Yanli MIAO ; Guangren YU ; Yinlong XU ; Yifeng LIU ; Weifeng HUANG ; Shaohong CHEN
China Pharmacist 2016;19(4):671-674
Objective: To investigate the effects of silk fibroin on the immobilization of thrombin. Methods: The immobilized thrombin was prepared using silk fibroin as the carrier and glutaraldehyde as the crosslinking agent. With activity yield as the index, the process conditions of silk fibroin immobilized thrombin were determined by an orthogonal test. Results:The optimum process con-ditions of immobilized thrombin treated with silk fibroin were as follows:the immobilization time was 6 h, the enzyme dosage was 2 400 NIH·g-1 casein, the temperature was 25℃ and pH was 7. 6. The activity recovery of immobilized thrombin was 67. 22%. Conclu-sion:Silk fibroin has the positive immobilization effect on thrombin.
2.Application effect of evolocumab combined with levocarnitine in patients with acute ST-elevation myocardial infarction after surgery
Lei WANG ; Liping MU ; Panpan YU ; Qianyu ZHANG ; Guangren GAO ; Jun ZHANG
Journal of Clinical Medicine in Practice 2024;28(15):76-79
Objective To investigate the effect of evolocumab combined with levocarnitine after emergency percutaneous coronary intervention(PCI)in patients with acute ST-segment elevation myo-cardial infarction(STEMI).Methods A total of 120 STEMI patients were selected and randomly di-vided into treatment group(60 cases)and control group(60 cases).The control group was given STEMI basic treatment plus levocarnitine,and the treatment group was given evolocumab on the basis of the control group.The therapeutic effectiveness,coronary artery microcirculation[B-type natriuretic peptide(BNP),left ventricular ejection fraction(LVEF)],coronary arteriole status[Thrombolysis in Myocardial Infarction(TIMI)risk score,preprotein converting enzyme subtilysin 9(PCSK9)and low density lipoprotein cholesterol(LDL-C)]and incidence of adverse reactions were compared between the two groups before and after treatment.Results After treatment,the total effective rate of treat-ment group was significantly higher than that of control group(P<0.05).After treatment,BNP level in two groups was significantly lower than before treatment,and the level in the treatment group was significantly lower than that in the control group(P<0.05);LVEF in the two groups was significantly higher than before treatment,and the treatment group was significantly higher than the control group(P<0.05).After treatment,the TIMI risk score of the two groups was significantly decreased,and the treatment group was significantly lower than the control group(P<0.05).The levels of PSCK9 and LDL-C in the two groups were significantly lower than before treatment,and the treatment group was significantly lower than the control group(P<0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Evolocumab combined with levocarnitine can improve cardiac function and coronary microcirculation in STEMI patients after emergency PCI,and has high safety.
3.Application effect of evolocumab combined with levocarnitine in patients with acute ST-elevation myocardial infarction after surgery
Lei WANG ; Liping MU ; Panpan YU ; Qianyu ZHANG ; Guangren GAO ; Jun ZHANG
Journal of Clinical Medicine in Practice 2024;28(15):76-79
Objective To investigate the effect of evolocumab combined with levocarnitine after emergency percutaneous coronary intervention(PCI)in patients with acute ST-segment elevation myo-cardial infarction(STEMI).Methods A total of 120 STEMI patients were selected and randomly di-vided into treatment group(60 cases)and control group(60 cases).The control group was given STEMI basic treatment plus levocarnitine,and the treatment group was given evolocumab on the basis of the control group.The therapeutic effectiveness,coronary artery microcirculation[B-type natriuretic peptide(BNP),left ventricular ejection fraction(LVEF)],coronary arteriole status[Thrombolysis in Myocardial Infarction(TIMI)risk score,preprotein converting enzyme subtilysin 9(PCSK9)and low density lipoprotein cholesterol(LDL-C)]and incidence of adverse reactions were compared between the two groups before and after treatment.Results After treatment,the total effective rate of treat-ment group was significantly higher than that of control group(P<0.05).After treatment,BNP level in two groups was significantly lower than before treatment,and the level in the treatment group was significantly lower than that in the control group(P<0.05);LVEF in the two groups was significantly higher than before treatment,and the treatment group was significantly higher than the control group(P<0.05).After treatment,the TIMI risk score of the two groups was significantly decreased,and the treatment group was significantly lower than the control group(P<0.05).The levels of PSCK9 and LDL-C in the two groups were significantly lower than before treatment,and the treatment group was significantly lower than the control group(P<0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Evolocumab combined with levocarnitine can improve cardiac function and coronary microcirculation in STEMI patients after emergency PCI,and has high safety.
4.Comparison of Pentacam and IOL Master for measurement of anterior segment parameters in eyes with cataracts
International Eye Science 2019;19(5):796-800
AIM: To compare anterior segment parameters in eyes with cataracts and different axial lengths measured with Pentacam and IOL Master.
METHODS: This study included 170 eyes of 143 patients diagnosed as cataract at Tangdu Hospital, Air Force Medical University. For each patient, anterior segment parameters were measured before surgery with Pentacam and IOL Master system, respectively.
RESULTS: There were no statistically significant differences in K1 and K2 values of eyes with long axial length(P>0.05). And there were statistically significant differences in K2 values(P<0.01), but not K1 values(P>0.05)of eyes with short and middle axial lengths. There were statistically significant differences in ACD values of eyes with any axial length(P<0.01). The Bland-Altman showed that ACD values of eyes with any axial length and K2 values of eyes with long and middle axial lengths were both in good agreement, and K1 values of eyes with any axial length were in great agreement.
CONCLUSION: Pentacam and IOL Master can be interchanged for keratometry in eyes with long axial length, but the measurements of keratometry in eyes with short and middle axial lengths and ACD of eyes with any axial length should be compared in clinical application.